📊 poll results
Moderna's cancer vaccine stock rocketed 177% then crashed 25% the next day — and RFK Jr had axed $500M in mRNA funding a year earlier. Who read this right?
🗳️ 11 votes so far 🏆 Leading: This was speculation running ahead of the facts. Merck and Moderna hadn't even released the actual numbers — "clinically meaningful improvement" is marketing language, not data. A single day move that nearly triples a company's value, followed by a 25% reversal, looks like hype correcting itself, not a rational re-pricing of a breakthrough. ⚖️ Split decision

Of 11 votes cast so far, This was speculation running ahead of the facts. Merck and Moderna hadn't even released the actual numbers — "clinically meaningful improvement" is marketing language, not data. A single day move that nearly triples a company's value, followed by a 25% reversal, looks like hype correcting itself, not a rational re-pricing of a breakthrough. leads with 45%.

The real story is political irony. A year after HHS Secretary RFK Jr. axed roughly $500 million from mRNA vaccine research over doubts about the technology, that same mRNA platform just produced one of oncology's biggest wins in years — proof mRNA's future was never just about COVID shots, and that the funding cuts were shortsighted. is second on 45%, close enough that a handful of votes could still turn it around.

Everyone who has answered so far is voting from China.

The poll is still live and picked up a vote today.

hewsay who say wut? 💬
📊 poll results
Moderna's cancer vaccine stock rocketed 177% then crashed 25% the next day — and RFK Jr had axed $500M in mRNA funding a year earlier. Who read this right?
45%
Leading answer
This was speculation running ahead of the facts. Merck and Moderna hadn't even released the actual numbers — "clinically meaningful improvement" is marketing language, not data. A single day move that nearly triples a company's value, followed by a 25% reversal, looks like hype correcting itself, not a rational re-pricing of a breakthrough.
11 votes so far
hewsay.com ↗

Discussion

Vote on one of these nextModerna Stock Exploded 177% in One Day on a Cancer Vaccine Breakthrough -- Is This Justified Science, Pure Hype, or a Short-Squeeze Overreaction?Moderna Stock Nearly Triples in a Day -- Cancer Breakthrough, Flu Shot Win, or Just a Short Squeeze?48% of Americans hope AI cures cancer or Alzheimer's — but only 15% trust the companies building it. Is that optimism justified?
react to this tea 👀
The market got it right. This is a genuine landmark — the first-ever Phase 3 proof that a personalized mRNA cancer vaccine actually works. The 177% pop reflected real science; the next-day dip was just normal profit-taking after an outsized rally, not doubt about the result.
This was speculation running ahead of the facts. Merck and Moderna hadn't even released the actual numbers — "clinically meaningful improvement" is marketing language, not data. A single day move that nearly triples a company's value, followed by a 25% reversal, looks like hype correcting itself, not a rational re-pricing of a breakthrough.
The real story is political irony. A year after HHS Secretary RFK Jr. axed roughly $500 million from mRNA vaccine research over doubts about the technology, that same mRNA platform just produced one of oncology's biggest wins in years — proof mRNA's future was never just about COVID shots, and that the funding cuts were shortsighted.